Specialty CRO QCTR Selects Medidata CTMS to Streamline Clinical Trials

SaaS-based Solution Will Help Research Organization Scale Trial Operations and Optimize Investigator Site Performance

NEW YORK, Aug 01, 2011 (BUSINESS WIRE) -- Medidata Solutions, a leading global provider of SaaS-based clinical development solutions, today announced that specialty contract research organization (CRO) QCTR Ltd. has selected Medidata CTMS, including its investigator site payment module, to manage the operations of all their clinical studies.

Scotland-based QCTR was founded in 2006 to fill a critical industry need for high-quality CRO expertise in central nervous system (CNS) clinical research, and has since managed a range of successful global Phase II and III studies in neurology, psychology and orphan indications. As their study pipeline grew, QCTR realized that a commercial trial management solution was necessary to efficiently do more with existing resources while maintaining their high quality and impressive track record in patient recruitment.

"Compared to other available systems, Medidata's SaaS-based CTMS solution offered much greater value in terms of richness of features, speed of set-up, flexibility, ease-of-use and global accessibility -- without requiring extensive up-front investment," said Susan McGoldrick, Managing Director, QCTR. "It's evident that Medidata CTMS was developed with CRO-specific needs in mind. We're especially excited about the opportunities to more proactively manage the performance of investigator sites and streamline how we pay them -- key aspects in our strategy to maintain our sites' high satisfaction and patient recruitment excellence as we scale our business."

QCTR anticipates that Medidata CTMS will greatly reduce the time and effort needed to track key milestones and operational metrics across their clinical studies and sites -- both from the perspective of data entry as well as timely access to information and reports. As a result, study managers and monitors should be able to maintain a tight handle on issues despite increased study volumes and quickly follow up with sites.

"Organizations such as QCTR clearly see Medidata CTMS as a new, better and cost-effective alternative to current CTMS choices: home-grown and spreadsheet-based tools that can't keep up with today's trial challenges or traditional CTMS software requiring substantial up-front investment and lengthy implementations," said Tarek Sherif, CEO, Medidata Solutions. "We're able to differentiate by giving our customers the best of two worlds: the flexibility and fast time-to-value of a SaaS-based solution, and the global reach, proven support and innovation of an industry leader such as Medidata."

About QCTR

QCTR is a niche CRO specializing in neurology, psychiatry and orphan diseases and is recognized internationally as experts in conducting proof of concept, phase II and phase III trials. QCTR was established in 2006 to fill the need of providing high quality, clinical research capabilities to companies operating the in the areas of neurology and psychiatry and orphan diseases. QCTR provides its clients with transparent budgeting, accurate and timely project information, access to key project personnel, and a practical knowledge of best practice in clinical study design in CNS and orphan disease areas.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of SaaS clinical development solutions that enhance the efficiency of customers' clinical trials. Medidata's advanced solutions lower the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.